Preclinical News and Research

RSS
MSKCC researchers study novel approach to treat metastatic melanoma

MSKCC researchers study novel approach to treat metastatic melanoma

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Ascenta Therapeutics, sanofi-aventis sign global licensing agreement for cancer drug candidates

Ascenta Therapeutics, sanofi-aventis sign global licensing agreement for cancer drug candidates

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences signs licensing agreement with PREVENT

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.